Previously, a recombinant replication-deficiency adenovirus type 5 (rAd5) based therapeutic vaccine rAdhGLi was developed to express intracellular granulysin, which demonstrated a direct killing effect on M. tuberculosis parasited in the macrophage ex vivo and also showed a significant therapeutic effect on TB mouse models via inhalation route 9. Here, GNLY is linked to tuberculosis.